Faron Pharmaceuticals Oy (LSE:FARN) EV-to-Revenue : (As of May. 24, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Faron Pharmaceuticals Oy's enterprise value is £146.44 Mil. Faron Pharmaceuticals Oy's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil. Therefore, Faron Pharmaceuticals Oy's EV-to-Revenue for today is .

The historical rank and industry rank for Faron Pharmaceuticals Oy's EV-to-Revenue or its related term are showing as below:

During the past 12 years, the highest EV-to-Revenue of Faron Pharmaceuticals Oy was 8580.06. The lowest was 6.93. And the median was 2972.71.

LSE:FARN's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.22
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-24), Faron Pharmaceuticals Oy's stock price is £1.925. Faron Pharmaceuticals Oy's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00. Therefore, Faron Pharmaceuticals Oy's PS Ratio for today is .

Faron Pharmaceuticals Oy EV-to-Revenue Historical Data

The historical data trend for Faron Pharmaceuticals Oy's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy EV-to-Revenue Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Faron Pharmaceuticals Oy's EV-to-Revenue

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faron Pharmaceuticals Oy's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's EV-to-Revenue falls into.

Faron Pharmaceuticals Oy EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Faron Pharmaceuticals Oy's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	146.442	/	0
	=

Faron Pharmaceuticals Oy's current Enterprise Value is £146.44 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

Faron Pharmaceuticals Oy (LSE:FARN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Faron Pharmaceuticals Oy's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.925	/	0
	=

Faron Pharmaceuticals Oy's share price for today is £1.925.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £0.00.

Faron Pharmaceuticals Oy EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines